Infectious disease scientists from Novartis, the University of Georgia and Washington State University have reported the discovery and early validation of a drug candidate for treating cryptosporidiosis,...

Scientists at The Scripps Research Institute (TSRI) have given new superpowers to a lifesaving antibiotic called vancomycin, an advance that could eliminate the threat of antibiotic-resistant infections...

In the fight against super bacteria, University at Buffalo scientists are relying on strength in numbers to win the battle against drug resistance. A team of researchers found that combinations of three...

Approximately one in four (22.1%) adults prescribed an antibiotic in an outpatient setting (such as a doctor’s office) for community-acquired pneumonia does not respond to treatment, according to a new...

The U.S. Food and Drug Administration today expanded the approved use of Kalydeco (ivacaftor) for treating cystic fibrosis. The approval triples the number of rare gene mutations that the drug can now...

Nearly one out of every three drugs approved by the Food and Drug Administration (FDA) have a new safety issue detected in the years after approval, says a Yale-led study. While most of the safety concerns...

The ALS Association, the only national nonprofit fighting amyotrophic lateral sclerosis (ALS) on every front, applauded the Food and Drug Administration’s (FDA) announcement Friday that it has approved...

Researchers in Ireland have developed a bioinspired antimicrobial treatment that can rapidly kill drug-resistant bacteria. The treatment consists of iodo-thiocyanate complexes, which are inspired by enzymes...

Many classes of common antibiotics, such as macrolides, quinolones, tetracyclines, sulfonamides and metronidazole, were associated with an increased risk of miscarriage in early pregnancy, according to...

The U.S. Food and Drug Administration  expanded the approved use of Stivarga (regorafinib) to include treatment of patients with hepatocellular carcinoma (HCC or liver cancer) who have been previously...